CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat

British Journal of Pharmacology

Volumn 155, Issue 7, 2008, Pages 1093-1103

  Zeller, J ^a   Poulsen, K T ^a   Sutton, J E ^a   Abdiche, Y N ^a   Collier, S ^a   Chopra, R ^a   Garcia, C A ^a,b   Pons, J ^a   Rosenthal, A ^a,c   Shelton, D L ^a  

^a PFIZER INC   (United States)

^b Arresto BioSciences   (United States)

^c MazorX Corporation   (United States)

Author keywords

Antibody; CGRP; Headache; Migraine; Neuropeptide; Vasodilatation

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; CALCITONIN GENE RELATED PEPTIDE[8-37]; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4901; MONOCLONAL ANTIBODY 7E9; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ARTERIAL PRESSURE; ARTERY DIAMETER; ARTICLE; BINDING ASSAY; BLOOD PRESSURE MEASUREMENT; BRAIN BLOOD FLOW; BRAIN BLOOD VESSEL; CARDIOVASCULAR FUNCTION; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; ELECTROSTIMULATION; EXPERIMENTAL MODEL; HEART RATE; HUMAN; HUMAN CELL; MALE; MENINGEAL ARTERY; MIGRAINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; SENSORY NERVE; SKIN BLOOD FLOW; VASODILATATION; VASOMOTOR REFLEX;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOOD PRESSURE; CALCITONIN GENE-RELATED PEPTIDE; DISEASE MODELS, ANIMAL; ELECTRIC STIMULATION; HALF-LIFE; HEART RATE; MALE; MENINGEAL ARTERIES; MIGRAINE DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; SKIN; VASODILATION;

EID: 56749176453     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.334     Document Type: Article

References (54)

1. Akerman S, Goadsby PJ (2005). Topiramate inhibits trigeminovascular activation: an intravital microscopy study. Br J Pharmacol 146: 7-14.
2. Alexander SP, Mathie A, Peters JA (2008). Guide to receptors and channels (GRAC), 3rd edition. Br J Pharmacol 153 (Suppl 2): S1-S209.
3. Amara SG, Arriza JL, Leff SE, Swanson LW, Evans RM, Rosenfeld MG (1985). Expression in brain of a messenger RNA encoding a novel neuropeptide homologous to calcitonin gene-related peptide. Science 229: 1094-1097.
4. Amara SG, Jonas V, Rosenfeld MG, Ong ES, Evans RM (1982). Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 298: 240-244.
5. Ando K, Pegram BL, Frohlich ED (1990). Hemodynamic effects of calcitonin gene-related peptide in spontaneously hypertensive rats. Am J Physiol 258 (2 Part 2): R425-R429.
6. Arulmani U, Maassenvandenbrink A, Villalon CM, Saxena PR (2004). Calcitonin gene-related peptide and its role in migraine pathophysiology. Eur J Pharmacol 500: 315-330.
7. Brain SD, Grant AD (2004). Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev 84: 903-934.
8. Buzzi MG, Moskowitz MA (1992). The trigemino-vascular system and migraine. Pathol Biol (Paris) 40: 313-317.
9. Cumberbatch MJ, Williamson DJ, Mason GS, Hill RG, Hargreaves RJ (1999). Dural vasodilation causes a sensitization of rat caudal trigeminal neurones in vivo that is blocked by a 5-HT1B/1D agonist. Br J Pharmacol 126: 1478-1486.
10. Denekas T, Troltzsch M, Vater A, Klussmann S, Messlinger K (2006). Inhibition of stimulated meningeal blood flow by a calcitonin gene-related peptide binding mirror-image RNA oligonucleotide. Br J Pharmacol 148: 536-543.
11. Doods H, Hallermayer G, Wu D, Entzeroth M, Rudolf K, Engel W et al. (2000). Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 129: 420-423.
12. Durham PL (2004). CGRP-receptor antagonists-a fresh approach to migraine therapy? N Engl J Med 350: 1073-1075.
13. Edvinsson L, Ekman R, Jansen I, McCulloch J, Uddman R (1987a). Calcitonin gene-related peptide and cerebral blood vessels: distribution and vasomotor effects. J Cereb Blood Flow Metab 7: 720-728.
14. Edvinsson L, Ekman R, Jansen I, Ottosson A, Uddman R (1987b). Peptide-containing nerve fibers in human cerebral arteries: immunocytochemistry, radioimmunoassay, and in vitro pharmacology. Ann Neurol 21: 431-437.
15. Edvinsson L, Goadsby PJ (1994). Neuropeptides in migraine and cluster headache. Cephalalgia 14: 320-327.
16. Edvinsson L, Nilsson E, Jansen-Olesen I (2007). Inhibitory effect of BIBN4096BS, CGRP(8-37), a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and nonperfused rat middle cerebral artery. Br J Pharmacol 150: 633-640.
17. Escott KJ, Brain SD (1993). Effect of a calcitonin gene-related peptide antagonist (CGRP8-37) on skin vasodilatation and oedema induced by stimulation of the rat saphenous nerve. Br J Pharmacol 110: 772-776.
18. Fischer JA, Born W (1985). Novel peptides from the calcitonin gene: expression, receptors and biological function. Peptides 6 (Suppl 3): 265-271.
19. Gangula PR, Zhao H, Supowit SC, Wimalawansa SJ, Dipette DJ, Westlund KN et al. (2000). Increased blood pressure in alpha-calcitonin gene-related peptide/calcitonin gene knockout mice. Hypertension 35 (1 Part 2): 470-475.
20. Goadsby PJ, Edvinsson L (1994). Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain 117 (Part 3): 427-434.
21. Goadsby PJ, Edvinsson L, Ekman R (1990). Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28: 183-187.
22. Holliger P, Hudson PJ (2005). Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23: 1126-1136.
23. Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ et al. (2008). Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 70: 1304-1312.
24. Holzer P (1998). Neurogenic vasodilatation and plasma leakage in the skin. Gen Pharmacol 30: 5-11.
25. Holzer P (2007). Role of visceral afferent neurons in mucosal inflammation and defense. Curr Opin Pharmacol 7: 563-569.
26. Juhl L, Edvinsson L, Olesen J, Jansen-Olesen I (2007). Effect of two novel CGRP-binding compounds in a closed cranial window rat model. Eur J Pharmacol 567: 117-124.
27. Kapoor K, Arulmani U, Heiligers JP, Willems EW, Doods H, Villalon CM et al. (2003). Effects of BIBN4096BS on cardiac output distribution and on CGRP-induced carotid haemodynamic responses in the pig. Eur J Pharmacol 475: 69-77.
28. Kohler G, Milstein C (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495-497.
29. Kohler G, Milstein C (1976). Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur J Immunol 6: 511-519.
30. Lambrecht N, Burchert M, Respondek M, Muller KM, Peskar BM (1993). Role of calcitonin gene-related peptide and nitric oxide in the gastroprotective effect of capsaicin in the rat. Gastroenterology 104: 1371-1380.
31. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J (2002). CGRP may play a causative role in migraine. Cephalalgia 22: 54-61.
32. Lu JT, Son YJ, Lee J, Jetton TL, Shiota M, Moscoso L et al. (1999). Mice lacking alpha-calcitonin gene-related peptide exhibit normal cardiovascular regulation and neuromuscular development. Mol Cell Neurosci 14: 99-120.
33. Oh-hashi Y, Shindo T, Kurihara Y, Imai T, Wang Y, Morita H et al. (2001). Elevated sympathetic nervous activity in mice deficient in alphaCGRP. Circ Res 89: 983-990.
34. Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U et al. (2004). Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350: 1104-1110.
35. Peroutka SJ (2005). Neurogenic inflammation and migraine: implications for the therapeutics. Mol Interv 5: 304-311.
36. Peskar BM, Wong HC, Walsh JH, Holzer P (1993). A monoclonal antibody to calcitonin gene-related peptide abolishes capsaicin-induced gastroprotection. Eur J Pharmacol 250: 201-203.
37. Petersen KA, Birk S, Doods H, Edvinsson L, Olesen J (2004). Inhibitory effect of BIBN4096BS on cephalic vasodilatation induced by CGRP or transcranial electrical stimulation in the rat. Br J Pharmacol 143: 697-704.
38. Petersen KA, Lassen LH, Birk S, Lesko L, Olesen J (2005). BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation. Clin Pharmacol Ther 77: 202-213.
39. Plourde V, Wong HC, Walsh JH, Raybould HE, Tache Y (1993). CGRP antagonists and capsaicin on celiac ganglia partly prevent post-operative gastric ileus. Peptides 14: 1225-1229.
40. Rosenfeld MG, Mermod J, Amara SG, Swanson LW, Sawchenko PE, Rivier J et al. (1983). Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature 304: 129-135.
41. Shen YT, Pittman TJ, Buie PS, Bolduc DL, Kane SA, Koblan KS et al. (2001). Functional role of alpha-calcitonin gene-related peptide in the regulation of the cardiovascular system. J Pharmacol Exp Ther 298: 551-558.
42. Storer RJ, Akerman S, Goadsby PJ (2004). Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol 142: 1171-1181.
43. Tan KK, Brown MJ, Hargreaves RJ, Shepheard SL, Cook DA, Hill RG (1995). Calcitonin gene-related peptide as an endogenous vasodilator: immunoblockade studies in vivo with an anti-calcitonin gene-related peptide monoclonal antibody and its Fab′ fragment. Clin Sci (Lond) 89: 565-573.
44. Troltzsch M, Denekas T, Messlinger K (2007). The calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS reduces neurogenic increases in dural blood flow. Eur J Pharmacol 562: 103-110.
45. Tsujikawa K, Yayama K, Hayashi T, Matsushita H, Yamaguchi T, Shigeno T et al. (2007). Hypertension and dysregulated proinflammatory cytokine production in receptor activity-modifying protein 1-deficient mice. Proc Natl Acad Sci USA 104: 16702-16707.
46. Uddman R, Edvinsson L, Ekblad E, Hakanson R, Sundler F (1986). Calcitonin gene-related peptide (CGRP): perivascular distribution and vasodilatory effects. Regul Pept 15: 1-23.
47. Uddman R, Hara H, Edvinsson L (1989). Neuronal pathways to the rat middle meningeal artery revealed by retrograde tracing and immunocytochemistry. J Auton Nerv Syst 26: 69-75.
48. Vater A, Jarosch F, Buchner K, Klussmann S (2003). Short bioactive Spiegelmers to migraine-associated calcitonin gene-related peptide rapidly identified by a novel approach: tailored-SELEX. Nucleic Acids Res 31: e130.
49. Williamson DJ, Hargreaves RJ (2001a). Neurogenic inflammation in the context of migraine. Microsc Res Tech 53: 167-178..
50. Williamson DJ, Hargreaves RJ, Hill RG, Shepheard SL (1997a). Intravital microscope studies on the effects of neurokinin agonists and calcitonin gene-related peptide on dural vessel diameter in the anaesthetized rat. Cephalalgia 17: 518-524.
51. Williamson DJ, Hargreaves RJ, Hill RG, Shepheard SL (1997b). Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat - intravital microscope studies. Cephalalgia 17: 525-531.
52. Williamson DJ, Shepheard SL, Cook DA, Hargreaves RJ, Hill RG, Cumberbatch MJ (2001b). Role of opioid receptors in neurogenic dural vasodilation and sensitization of trigeminal neurones in anaesthetized rats. Br J Pharmacol 133: 807-814.
53. Wong HC, Tache Y, Lloyd KC, Yang H, Sternini C, Holzer P et al. (1993). Monoclonal antibody to rat alpha-CGRP: production, characterization, and in vivo immunoneutralization activity. Hybridoma 12: 93-106.
54. Zimmermann U, Fischer JA, Muff R (1995). Adrenomedullin and calcitonin gene-related peptide interact with the same receptor in cultured human neuroblastoma SK-N-MC cells. Peptides 16: 421-424.